Practicalities For AI-Enabled Devices As Digital (R)evolution Picks Up Pace
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
Medtech Insight - March 31, 2026

People On The Move: Appointments At Opella, Bodywise, Wellnex
A round up of the latest consumer health people moves: Opella names Europe & LATAM head; Bodywise appoints CEO and changes ownership structure; Wellnex makes board move.
HBW Insight - March 31, 2026

Merck & Co. Taps Infinimmune For AI-Guided Antibody Discovery
Deal Snapshot: Merck is paying up to $838m to work with Infinimmune's antibody discovery platform, which identifies antibodies native to the human body and combines that with AI-driven engineering.
Scrip - March 31, 2026

UK Consumer Health Market In Good Shape Despite Slow Volume Growth
Despite modest volume growth, NielsenIQ data shows that the UK consumer health market remains structurally strong, with preventative habits, digital channels and rising self?care confidence underpinning double?digit value growth in 2025.
HBW Insight - March 31, 2026

Biosimilar Streamlining Takes A Further Step Forward In Europe
Marking the latest definite step towards a streamlined regulatory pathway for biosimilars as standard, the EMA has formally adopted its reflection paper on a tailored clinical approach in biosimilar development.
Generics Bulletin - March 31, 2026

Biogen To Acquire Apellis For $5.6bn To Expand Rare Disease Portfolio
The acquisition is expected to bring immediate commercial revenue and strengthen Biogen’s long-term growth profile.
Scrip - March 31, 2026

Perspective: Navigating Medical Device Development From Bench To Market
The global medical device market reached $623.37 billion in 2026 and should exceed $1.08 trillion by 2035. Despite this explosive growth, the journey from research and development to commercialization remains fraught with regulatory complexities, evolving market dynamics, and technical disruptions.
Medtech Insight - March 31, 2026

CapVest Hints At ‘Ambitious Plans’ For Stada As It Completes Takeover
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
Generics Bulletin - March 31, 2026

AstraZeneca’s ALXN1850 On Blockbuster Trajectory Despite Mixed Phase III Results
The next-gen hypophosphatasia treatment failed to reach significance in adult-onset patients, but AstraZeneca will hope regulators approve it across all patient groups as a successor to Strensiq.
Scrip - March 31, 2026

Eli Lilly To Buy Centessa For $6.3bn, Gaining Phase II Narcolepsy Drug
Lilly makes one if its biggest acquisitions in recent years to acquire orexin-based therapies for sleep disorders, an area that is seeing intense development activity with multiple potential entrants set to enter the fray.
Scrip - March 31, 2026

Stock Watch: Vaccine Sales And Super Tankers
Measles outbreaks in young children in the US and UK have occurred in the face of antivax sentiment. But a federal judge’s ruling against the ACIP’s reformation and its actions and a meningitis outbreak in young adults in the UK may be enough to sway the tide.
Scrip - March 31, 2026

US Supply Chain Challenges Increase In Shadow Of Iran War
The AAM has become the latest generics and biosimilars industry body to warn of potential supply-chain threats as the war in Iran and the Middle East continues, suggesting that a prolonged conflict could raise the risk of shortages as suppliers are “starting to experience more challenges.”
Generics Bulletin - March 31, 2026

Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data
Phase III psoriasis data adds further momentum to envudeucitinib's bid in TYK2 with a potential launch in 2027.
Scrip - March 31, 2026

US FDA Parsing DSHEA Language For Answer: ‘Are There Any Limits’ To Dietary Substance Types?
“Are there any limits to what this category can encompass? That's the question of the day,” says ODSP director Cara Welch at public meeting to continue discussion with industry launched in 2019 about whether only ingredients found in conventional foods can be NDIs.
HBW Insight - March 31, 2026

Curogen Attracts Global Investors As Novel Autoimmune, Protein Assets Progress
Curogen CEO shares what’s behind keen global investor interest in Korean venture's latest financing round and what differentiates its next-generation autoimmune disease and dermatology assets.
Scrip - March 31, 2026